CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation

This study has been completed.
Sponsor:
Information provided by:
Conor Medsystems
ClinicalTrials.gov Identifier:
NCT00422435
First received: January 15, 2007
Last updated: October 23, 2008
Last verified: October 2008
  Purpose

This study is designed to evaluate the performance and safety of a new catheter system.


Condition Intervention Phase
Coronary Disease
Device: CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The PreCiSE Trial: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation

Resource links provided by NLM:


Further study details as provided by Conor Medsystems:

Primary Outcome Measures:
  • Device Success [ Time Frame: At procedure or hospital discharge ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lesion success [ Time Frame: 30 days, 6 months and 12 months ] [ Designated as safety issue: No ]
  • Procedure success [ Time Frame: 30 days, 6 months and 12 months ] [ Designated as safety issue: No ]
  • Acute Device Performance [ Time Frame: Index procedure ] [ Designated as safety issue: No ]
  • In hospital, 30-day, 6-month, 12-month MACE [ Time Frame: 30-day, 6-month, 12-month ] [ Designated as safety issue: Yes ]

Enrollment: 107
Study Start Date: January 2007
Study Completion Date: May 2008
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug eluting stent
CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
Device: CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
Paclitaxel-Eluting Coronary Stent

Detailed Description:

This study is designed to evaluate acute Device Success, defined as attainment of <50% residual stenosis of the target lesion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient ≥18 years of age
  • Eligible for percutaneous coronary intervention
  • Documented stable or unstable angina pectoris (Canadian Cardiovascular Society Classification 1, 2, 3, or 4), documented ischemia, or documented silent ischemia
  • Left ventricular ejection fraction ≥25% documented within the last 6 wks
  • Acceptable candidate for coronary artery bypass graft surgery
  • A single de novo lesion per study subject may be treated with the study device
  • Each target lesion may be composed of multiple lesions but must be completely coverable by 1 study stent
  • Cumulative target lesion length per vessel ≤30 mm based on a visual estimate
  • RVD ≥2.5 mm to ≤3.0 mm based on a visual estimate
  • Target lesion diameter stenosis ≥50% and <100% based on a visual estimate
  • Target vessel has not undergone prior revascularization within the preceding 6 months
  • Target lesion must be a minimum 10 mm distance from any previously treated segment of the target vessel

Exclusion Criteria:

  • Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: Translute or PLGA
  • Planned treatment with any other PCI device in the target vessel(s)
  • MI within 72 hours prior to the index procedure
  • Patient is in cardiogenic shock
  • Cerebrovascular Accident within the past 6 months
  • Acute or chronic renal dysfunction (creatinine >2.0 mg/dl or >150 µmol/L)
  • Contraindication to ASA or to clopidogrel
  • Thrombocytopenia (platelet count <100, 000/mm3)
  • Active gastrointestinal bleeding within the past three months
  • Any prior true anaphylactic reaction to contrast agents
  • Patient is currently, or has been treated with paclitaxel (systemic) within 12 months of the index procedure
  • Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure, or lactating, or intends to become pregnant during the study
  • Life expectancy of less than 24 months due to other medical conditions
  • Co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
  • Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  • Left main coronary artery disease (stenosis >50%), whether protected or unprotected
  • Target lesion is ostial in location (within 3.0 mm of vessel origin)
  • Target lesion and/or target vessel proximal to the target lesion is severely calcified by visual estimation
  • Target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter that requires intervention
  • Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1)
  • Angiographic presence of probable or definite thrombus
  • Target vessel will be pre-treated with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
  • Prior coronary intervention using brachytherapy to any segment of the target vessel
  • The target vessel has had prior drug-eluting stent placement to vessel segment (or branch) proximal to intended target lesion site
  • Angiographic restenosis of any segment of the target vessel that has undergone prior percutaneous coronary intervention
  • Angiographic evidence of atherosclerotic disease with > 50% diameter stenosis (by visual estimate) proximal or distal to the target lesion (applies to the major epicardial portion of the target vessel and contiguous vessel segment if the target lesion is located in a branch vessel)
  • Prior surgical revascularization of the target vessel with patent graft (saphenous vein graft or arterial conduit)
  • Target lesion lies within 10 mm of prior surgical anastomosis site
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00422435

Locations
Belgium
UH Gasthuisberg
Leuven, Belgium, 3000
Sponsors and Collaborators
Conor Medsystems
Investigators
Principal Investigator: Christophe Dubois, M.D. UH Gasthuisberg
  More Information

No publications provided

Responsible Party: Christophe Dubois, M.D. Principal Investigator, UH Gasthuisberg
ClinicalTrials.gov Identifier: NCT00422435     History of Changes
Other Study ID Numbers: The PreCiSE Trial: CP-03
Study First Received: January 15, 2007
Last Updated: October 23, 2008
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Keywords provided by Conor Medsystems:
Percutaneous coronary intervention (PCI)
Drug eluting stent (DES)

Additional relevant MeSH terms:
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 20, 2014